Plasmid-mediated mcr-1 in carbapenem-susceptible Escherichia coli ST156 causing a blood infection: an unnoticeable spread of colistin resistance in Brazil?

Carregando...
Imagem de Miniatura
Citações na Scopus
31
Tipo de produção
article
Data de publicação
2017
Título da Revista
ISSN da Revista
Título do Volume
Editora
HOSPITAL CLINICAS, UNIV SAO PAULO
Autores
MORAIS, Carlos
MARTINS, Layla Farage
SILVA, Aline Maria da
SETUBAL, Joao Carlos
Citação
CLINICS, v.72, n.10, p.642-644, 2017
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
OBJECTIVE: We describe an IncX4 pHC891/16mcr plasmid carrying mcr-1 in a colistin-resistant and carbapenem-susceptible E. coli isolate (HC891/16), ST156, which caused a blood infection in a Brazilian patient with gallbladder adenocarcinoma. METHODS: Strain HC891/16 was subjected to whole genome sequencing using the MiSeq Platform (Illumina, Inc., USA). Assembly was performed using Mira and ABACAS. RESULTS: The isolates showed resistance only to ciprofloxacin, ampicillin and cefoxitin, and whole-genome sequencing revealed the presence of aac(6')Ib-cr and bla(TEM1). CONCLUSION: Our findings warn of the possible silent dissemination of colistin resistance by carbapenem-susceptible mcr-1 producers, as colistin susceptibility is commonly tested only among carbapenem-resistant isolates.
Palavras-chave
Colistin Resistance, Polymyxin Resistance, Escherichia Coli, Carbapenem-Susceptible, ST156
Referências
  1. Aires CAM, 2017, ANTIMICROB AGENTS CH, V61
  2. Assefa S, 2009, BIOINFORMATICS, V25, P1968, DOI 10.1093/bioinformatics/btp347
  3. Chevreux B, 1999, COMP SCI BIOL P GER, V99, P45
  4. Clinical and Laboratory Standards Institute [CLSI], 2012, M07A9 CLSI
  5. Di Pilato V, 2016, ANTIMICROB AGENTS CH, V60, P5612, DOI 10.1128/AAC.01075-16
  6. Du H, 2016, LANCET INFECT DIS, V16, P287, DOI 10.1016/S1473-3099(16)00056-6
  7. Falgenhauer L, 2016, LANCET INFECT DIS, V16, P282, DOI 10.1016/S1473-3099(16)00009-8
  8. Fernandes MR, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.17.30214
  9. Fernandes MR, 2016, ANTIMICROB AGENTS CH, V60, P6415, DOI 10.1128/AAC.01325-16
  10. Hasman H, 2015, EUROSURVEILLANCE, V20, P2, DOI 10.2807/1560-7917.ES.2015.20.49.30085
  11. Li AQ, 2016, ANTIMICROB AGENTS CH, V60, P4351, DOI 10.1128/AAC.00550-16
  12. Liu YY, 2016, LANCET INFECT DIS, V16, P161, DOI 10.1016/S1473-3099(15)00424-7
  13. Mediavilla JR, 2016, MBIO, V7, DOI 10.1128/mBio.01191-16
  14. Olaitan AO, 2016, LANCET INFECT DIS, V16, P147, DOI 10.1016/S1473-3099(15)00540-X
  15. Olaitan AO, 2016, INT J ANTIMICROB AG, V47, P1, DOI 10.1016/j.ijantimicag.2015.11.009
  16. Rapoport M, 2016, ANTIMICROB AGENTS CH, V60, P4412, DOI 10.1128/AAC.00573-16
  17. Rossi F, 2017, BRAZ J INFECT DIS, V21, P98, DOI 10.1016/j.bjid.2016.09.011
  18. Skov RL, 2016, EUROSURVEILLANCE, V21, P2, DOI 10.2807/1560-7917.ES.2016.21.9.30155
  19. Stoesser N, 2016, LANCET INFECT DIS, V16, P285, DOI 10.1016/S1473-3099(16)00010-4
  20. Vasconcelos ATR, 2015, DIAGN MICR INFEC DIS, V83, P382, DOI 10.1016/j.diagmicrobio.2015.08.006
  21. Yang RS, 2016, ANTIMICROB AGENTS CH, V60, P6899, DOI 10.1128/AAC.01365-16
  22. Zankari E, 2012, J ANTIMICROB CHEMOTH, V67, P2640, DOI 10.1093/jac/dks261
  23. Zurfluh K, 2016, ANTIMICROB AGENTS CH, V60, P5589, DOI 10.1128/AAC.00935-16